Madrigal Phase III Success In NASH Spurs Buyout Speculation
With resmetirom hitting its co-primary endpoints, Madrigal intends to file the THRβ agonist for approval during H1 2023 in the liver disease, an unmet medical need with blockbuster earnings potential.
You may also be interested in...
Intercept, Madrigal Get Ready For NASH Commercialization
With a 22 June US FDA action date for obeticholic acid in non-alcoholic steatohepatitis, Intercept is thinking ahead to launch plans. Madrigal said it plans a Q2 filing for its NASH drug and hopes to find an ex-US commercial partner.
ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA
In a draft assessment, the non-profit said Madrigal’s non-alcoholic steatohepatitis candidate might yield cost savings over a lifetime of care. Both drugs seem to offer incremental benefits for survival and quality of life.
Financing Available For Some, But Not All Biopharma Companies In 2023
Investors, advisors and CEOs at the J.P. Morgan Healthcare Conference and Biotech Showcase were somewhat optimistic about fundraising this year, but noted certain companies may have to call it quits.